Edoxaban (Savaysa) can reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation.
Medication Pearl of the Day: Edoxaban (Savaysa)
Indication: Edoxaban (Savaysa) is a factor Xa inhibitor indicated to reduce the risk of stroke and systemic embolism (SE) in patients with nonvalvular atrial fibrillation (NVAF).
- For NVAF: The recommended dose is 60 mg once daily in patients with CrCL >50 to ≤ 95 mL/min. Do not use edoxaban in patients with CrCL > 95 mL/min.
- For deep vein thrombosis/pulmonary embolism: The recommended dose is 60 mg once daily (2.2). The recommended dose is 30 mg once daily for patients with CrCL 15 to 50 mL/min or body weight less than or equal to 60 kg or who use certain P-gp inhibitors.
- Dosage forms: Tablets 60 mg, 30 mg, and 15 mg.
- Adverse events: Bleeding, rash, abnormal liver function.
- Mechanism of action: Edoxaban is a selective inhibitor of FXa. It does not require antithrombin III for antithrombotic activity.
- Manufacturer: Daiichi Sankyo